Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

Fischer, Ute, Forster, Michael, Rinaldi, Anna, Risch, Thomas, Sungalee, Stephanie, Warnatz, Hans-Joerg, Bornhauser, Beat, Gombert, Michael, Kratsch, Christina, Stuetz, Adrian M., Sultan, Marc, Tchinda, Joelle, Worth, Catherine L., Amstislavskiy, Vyacheslav, Badarinarayan, Nandini, Baruchel, Andre, Bartram, Thies, Basso, Giuseppe, Canpolat, Cengiz, Cario, Gunnar, Cave, Helene, Dakaj, Dardane, Delorenzi, Mauro, Dobay, Maria Pamela, Eckert, Cornelia, Ellinghaus, Eva, Eugster, Sabrina, Frismantas, Viktoras, Ginzel, Sebastian, Haas, Oskar A., Heidenreich, Olaf, Hemmrich-Stanisak, Georg, Hezaveh, Kebria, Hoell, Jessica I., Hornhardt, Sabine, Husemann, Peter, Kachroo, Priyadarshini, Kratz, Christian P., te Kronnie, Geertruy, Marovca, Blerim, Niggli, Felix, McHardy, Alice C., Moorman, Anthony V., Panzer-Gruemayer, Renate, Petersen, Britt S., Raeder, Benjamin, Ralser, Meryem, Rosenstiel, Philip, Schaefer, Daniel, Schrappe, Martin, Schreiber, Stefan, Schuette, Moritz, Stade, Bjoern, Thiele, Ralf, von der Weid, Nicolas, Vora, Ajay, Zaliova, Marketa, Zhang, Langhui, Zichner, Thomas, Zimmermann, Martin, Lehrach, Hans, Borkhardt, Arndt, Bourquin, Jean-Pierre, Franke, Andre, Korbel, Jan O., Stanulla, Martin and Yaspo, Marie-Laure (2015) Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options Nature Genetics, 47 (9). 1020-+.

Full text not available from this repository.

Abstract

TCF3-HLF-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. We identified recurrent intragenic deletions of PAX5 or VPREB1 in constellation with the fusion of TCF3 and HLF. Moreover somatic mutations in the non-translocated allele of TCF3 and a reduction of PAX5 gene dosage in TCF3-HLF ALL suggest cooperation within a restricted genetic context. The enrichment for stem cell and myeloid features in the TCF3-HLF signature may reflect reprogramming by TCF3-HLF of a lymphoid-committed cell of origin toward a hybrid, drug-resistant hematopoietic state. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in clinical development. Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199). This integrated approach thus provides alternative treatment options for this deadly disease.

Document Type: Article
Additional Information: Times Cited: 0
Research affiliation: Kiel University
Kiel University > Kiel Marine Science
OceanRep > The Future Ocean - Cluster of Excellence
Refereed: Yes
ISSN: 1061-4036
Projects: Future Ocean
Date Deposited: 20 Oct 2016 10:51
Last Modified: 20 Oct 2016 10:51
URI: http://eprints.uni-kiel.de/id/eprint/32476

Actions (login required)

View Item View Item